MET and non-small cell lung carcinoma: MET gene amplification resulting in protein overexpression and constitutive activation of the MET receptor has been described in NSCLC, gastric carcinoma and HCC, as well as in preclinical models [24] ‘addicted’ to the MET signaling pathway.